oHSV are engineered viruses that attack cancer cells. They also stimulate the immune system to act against cancer cells. Timothy P. Cripe, MD, PhD, of Nationwide Children’s Hospital and The Ohio State University has provided a suite of immunotherapy biotechnologies to Open Therapeutics for global scientific collaboration. This suite of ViruBots have peer review published in vivo results. Assisted by Drs. Su, Guo, Samy, Krishnamoorthy, Dr. Cripe is developing these ViruBots to target fourteen different cancer types as well as neoplasm.
